Group 1 - The National Health Commission of China has issued notifications prohibiting the use of "ileal-jejunal anastomosis" for the treatment of type 2 diabetes and "cervical deep lymphatic vessel/lymph node-venous anastomosis" for Alzheimer's disease treatment [2][3] - The cervical deep lymphatic vessel/lymph node-venous anastomosis is primarily used for treating stubborn lymphedema, but its application for Alzheimer's disease lacks clear indications and contraindications, as well as high-quality evidence supporting its safety and efficacy [2] - The ileal-jejunal anastomosis, used for restoring intestinal continuity, has been deemed to lack foundational theoretical support and high-quality evidence for its safety and efficacy in treating type 2 diabetes [3] Group 2 - The domestic anastomosis device market may be impacted by these prohibitions, with the top 10 manufacturers in China including Johnson & Johnson, Covidien, Frankmann, Yisi Medical, Tianchen Medical, Palt Medical, David Medical, Rich Surgical, Yintukang Medical, and Brolansense [3] - Relevant listed companies in this sector include Dongxing Medical and Tianchen Medical, which may face challenges due to the new regulations [3]

Core Viewpoint - The National Health Commission has prohibited the use of jejunoileal anastomosis for the treatment of type 2 diabetes and cervical deep lymphatic/lymph node-venous anastomosis for Alzheimer's disease treatment due to safety and efficacy concerns [1][2] Group 1: Jejunoileal Anastomosis - The jejunoileal anastomosis is primarily used for intestinal obstruction, tumor resection reconstruction, or congenital deformity repair, but its application in diabetes treatment has been deemed unsafe and ineffective [1][2] - The procedure may lead to severe complications such as liver failure and malnutrition, and it has been eliminated from clinical use in the weight loss metabolic field due to high complication rates [2] Group 2: Cervical Deep Lymphatic/Lymph Node-Venous Anastomosis - The cervical deep lymphatic/lymph node-venous anastomosis lacks direct evidence from preclinical studies for its application in Alzheimer's disease treatment, and it is still in the early exploratory stage of clinical research [2] - Local health authorities are required to investigate the clinical application of this procedure and ensure that medical institutions immediately cease its use while enhancing regulatory oversight [2]

Core Viewpoint - The National Health Commission of China has issued notifications prohibiting the use of two surgical procedures: "cervical deep lymphatic vessel/vein anastomosis" for Alzheimer's disease and "jejunum-ileum anastomosis" for type 2 diabetes treatment, due to concerns over their safety and efficacy [1][4][12]. Group 1: Alzheimer's Disease and Surgical Procedure - The "cervical deep lymphatic vessel/vein anastomosis" (LVA) is deemed to be in the early exploratory stage of clinical research, lacking clear indications and contraindications, as well as high-quality evidence supporting its safety and effectiveness [4][10]. - The procedure has been evaluated by experts, who concluded that its application in treating Alzheimer's disease is not supported by sufficient clinical evidence, and it poses potential risks that may outweigh benefits for patients with mild symptoms [9][10]. - The National Health Commission has mandated local health authorities to ensure that medical institutions cease the use of LVA for Alzheimer's treatment and to provide follow-up services for affected patients [11]. Group 2: Type 2 Diabetes and Surgical Procedure - The "jejunum-ileum anastomosis" has been evaluated and found to have uncertain safety and effectiveness for treating type 2 diabetes, with potential severe complications such as liver failure and malnutrition [12][14]. - Although some studies suggest that this procedure may improve blood sugar levels post-surgery, the overall clinical evidence remains limited, and it has not been included in the latest diabetes treatment guidelines [13][14]. - The National Health Commission has instructed health authorities to monitor and regulate the clinical application of this procedure, ensuring that institutions stop its use for diabetes treatment and enhance public health education [14].

Core Viewpoint - The National Health Commission of China has issued notifications to prohibit the use of "cervical deep lymphatic-venous anastomosis" for Alzheimer's treatment and "ileal-jejunal anastomosis" for type 2 diabetes treatment due to safety and efficacy concerns [1][2][5][6]. Group 1: Alzheimer's Disease and Surgical Procedures - The "cervical deep lymphatic-venous anastomosis" (LVA) is considered to be in the early exploratory stage of clinical research, lacking clear indications and contraindications, as well as high-quality evidence for safety and efficacy [1][5]. - Alzheimer's disease, characterized by cognitive dysfunction and behavioral impairment, affects over 50 million people globally, with no effective cure currently available [3][5]. - The procedure's complexity and the risks associated with the delicate nature of lymphatic vessels raise concerns about its potential benefits versus risks, especially for patients with mild symptoms [4][5]. Group 2: Type 2 Diabetes and Surgical Procedures - The "ileal-jejunal anastomosis" has been evaluated and found to have uncertain safety and efficacy for treating type 2 diabetes, with potential severe complications such as liver failure and malnutrition [6][7]. - Although some studies suggest that this procedure may lower blood sugar levels post-surgery, it remains in the exploratory phase and has not been included in the latest diabetes management guidelines [7][8]. - The National Health Commission emphasizes the need for rigorous oversight and management of clinical applications of these surgical techniques, urging local health authorities to enforce the cessation of their use [2][8].

Core Viewpoint - The National Health Commission of China has issued two important notifications prohibiting the use of specific surgical techniques for treating Alzheimer's disease and type 2 diabetes due to safety and efficacy concerns [2][4][5]. Group 1: Prohibition of Surgical Techniques - The "cervical deep lymphatic vessel/lymph node-venous anastomosis" technique is prohibited for Alzheimer's treatment as it is still in the early exploratory stage of clinical research, lacking clear indications and contraindications, and high-quality evidence for safety and efficacy [4]. - The "jejunum-ileum anastomosis" technique is banned for type 2 diabetes treatment due to uncertain safety and efficacy, with potential severe complications such as liver failure and malnutrition [5]. Group 2: Regulatory Actions - Local health administrative departments are required to ensure that medical institutions cease the use of the prohibited techniques for the specified conditions and provide follow-up services for affected patients [4][5]. - The National Health Commission will guide qualified medical institutions to strengthen clinical research design once sufficient preclinical research evidence is available, and will reassess the clinical application of these techniques based on research outcomes [4].

Core Viewpoint - The article discusses the recent bans by the National Health Commission on two surgical procedures for treating Alzheimer's disease and type 2 diabetes, highlighting the rise of unproven medical technologies and the need for regulatory oversight [1][2]. Group 1: Surgical Procedures Banned - The National Health Commission has prohibited the clinical application of "cervical deep lymphatic vessel/lymph node-venous anastomosis" for Alzheimer's treatment and "ileal-jejunal anastomosis" for type 2 diabetes treatment due to lack of authoritative guidelines and high-level medical evidence [1][2]. - Both surgical techniques have been applied beyond their intended indications in some hospitals, leading to concerns about patient safety and the potential for serious complications [2][10]. Group 2: Clinical Evidence and Guidelines - The latest "Chinese Diabetes Prevention and Treatment Guidelines" (2024 edition) does not include ileal-jejunal anastomosis as a recommended metabolic surgery, despite its promotion in some hospitals [5][6]. - Research on the use of ileal-jejunal anastomosis for type 2 diabetes is limited, with few studies published in low-impact journals [6]. Group 3: Emerging Technologies - The "cervical deep lymphatic vessel-venous anastomosis" (LVA) is a novel technique being explored for Alzheimer's treatment, with ongoing clinical research in several hospitals across China [12][19]. - LVA has shown potential in treating neurodegenerative diseases, but its mechanisms and effectiveness remain unproven, necessitating further clinical trials and standardized protocols [15][19]. Group 4: Regulatory Actions - The National Health Commission has emphasized the need for strict regulatory oversight of clinical trials and the application of new surgical techniques, urging local health authorities to monitor and halt unauthorized practices [17][18].

Core Viewpoint - The National Health Commission has issued notifications prohibiting the use of "jejunum-ileum anastomosis" for the treatment of type 2 diabetes and "cervical deep lymphatic vessel/lymph node-venous anastomosis" for Alzheimer's disease, citing lack of safety and efficacy evidence [2][6]. Group 1: Jejunum-Ileum Anastomosis - Jejunum-ileum anastomosis is a surgical procedure that connects the jejunum and ileum, primarily used for bowel obstruction, tumor resection reconstruction, or congenital malformation repair [3]. - The assessment concluded that the safety and efficacy of jejunum-ileum anastomosis for diabetes treatment are uncertain, with potential severe complications such as liver failure and malnutrition [4]. - Local health authorities are required to ensure that medical institutions cease the use of this technique for diabetes treatment and enhance regulatory oversight [5]. Group 2: Cervical Deep Lymphatic Vessel/Venous Anastomosis - Cervical deep lymphatic vessel/lymph node-venous anastomosis is a microsurgical technique that connects lymphatic vessels or nodes to nearby veins, mainly used for treating persistent lymphedema [7]. - The evaluation indicated that this technique is still in the early exploratory stage of clinical research, lacking direct evidence for safety, efficacy, and economic viability [8]. - Provincial health authorities must oversee the cessation of this technique's application for Alzheimer's treatment and guide qualified medical institutions in conducting clinical research in a scientific and regulated manner [9].

Core Viewpoints - The National Health Commission has issued notifications prohibiting the use of "jejunum-ileum anastomosis" for treating type 2 diabetes and "cervical deep lymphatic vessel/vein anastomosis" for treating Alzheimer's disease due to lack of sufficient evidence supporting their safety and efficacy [1][2]. Group 1: Jejunum-Ileum Anastomosis for Type 2 Diabetes - The National Health Commission assessed the use of "jejunum-ileum anastomosis" for type 2 diabetes and found it lacks theoretical support and high-quality evidence, leading to its prohibition [1]. - Local health authorities are required to ensure that medical institutions cease using this technique for diabetes treatment, with serious consequences for non-compliance [1]. Group 2: Cervical Deep Lymphatic Vessel/Vein Anastomosis for Alzheimer's Disease - The National Health Commission has identified that "cervical deep lymphatic vessel/vein anastomosis" is still in the early exploratory stage of clinical research, with unclear indications and contraindications, resulting in its prohibition for Alzheimer's treatment [2][3]. - Local health authorities must monitor and ensure that medical institutions stop using this technique, while also providing follow-up services for affected patients [3]. - The National Health Commission will consider re-evaluating the clinical application of this technique once sufficient preclinical research evidence is available [3].

Core Viewpoint - The National Health Commission of China has prohibited the use of "cervical deep lymphatic vessel/lymph node-venous anastomosis" for the treatment of Alzheimer's disease due to insufficient clinical evidence supporting its safety and efficacy [1][4]. Group 1: Regulatory Actions - The National Health Commission organized an expert evaluation of the technique, concluding that it is still in the early exploratory stage of clinical research, with unclear indications and contraindications [1][4]. - Local health authorities are required to ensure that medical institutions cease the use of this technique for Alzheimer's treatment and provide follow-up services for affected patients [1][5]. - Institutions and personnel continuing to use this technique post-notification will face serious consequences under relevant health laws and regulations [2]. Group 2: Technical Overview - "Cervical deep lymphatic vessel/lymph node-venous anastomosis" is a microsurgical technique that connects lymphatic vessels or nodes to nearby veins, primarily used for treating persistent lymphedema [3]. Group 3: Evaluation Findings - The evaluation found a lack of direct evidence from preclinical studies regarding the safety, efficacy, and economic viability of the technique for Alzheimer's treatment [4]. - The technique's application for Alzheimer's disease lacks high-quality evidence from clinical studies and health economics [4]. Group 4: Implementation Guidelines - Provincial health authorities must fulfill their responsibilities in managing the clinical application of medical technologies and enhance daily supervision of medical institutions [5]. - Local health departments should conduct investigations into the clinical application of the technique and ensure compliance with the prohibition [5].

Core Viewpoint - The National Health Commission has issued two important notifications prohibiting specific surgical techniques for the treatment of Alzheimer's disease and type 2 diabetes, emphasizing the need for clinical application management and evidence-based support for medical practices [1]. Group 1: Alzheimer's Disease Treatment - The notification prohibits the use of "cervical deep lymphatic vessel/lymph node-venous anastomosis" for treating Alzheimer's disease due to its early exploratory stage in clinical research [1]. - Expert evaluations indicate that the indications and contraindications for this technique are not clearly defined, and there is a lack of high-quality evidence supporting its safety and effectiveness [1]. Group 2: Type 2 Diabetes Treatment - The notification also bans the use of "jejunum-ileum anastomosis" for the treatment of type 2 diabetes, reflecting similar concerns regarding the clinical application of this surgical method [1]. - The decision underscores the importance of rigorous evaluation and evidence before adopting new medical technologies in clinical settings [1].